Private Equity

  • December 11, 2017

    Has Litigation Finance Shed Its Stigma?

    Once a taboo topic in the halls of BigLaw, litigation finance is winning over converts. And the peer pressure is building for rival law firms to join the bandwagon.

  • December 11, 2017

    Why Investors Are Taking The Leap To 3rd-Party Funding

    They often don’t know exactly what they’re buying, and there’s an ever-present chance they could come up empty in a given case. Here’s why investors are flocking to litigation finance anyway.

  • December 11, 2017

    What Your Colleagues Think Of Litigation Finance

    We asked, and you answered. Here are the results of Law360’s inaugural survey on third-party legal funding.

  • December 11, 2017

    KKR, FS Investments Team Up For $18B Biz Development Co.

    Alternative investment manager FS Investments said Monday it is teaming up with KKR & Co. LP to create an $18 billion business development company, ending a partnership with Blackstone Group LP’s credit investment platform.

  • December 11, 2017

    Deals Rumor Mill: Disney, Ascension Health, GGP

    A deal between Disney and 21st Century Fox could come this week, Ascension Health and Providence St. Joseph Health are in talks to merge, and GGP has declined Brookfield Property Partners LP’s $14.8 billion buyout bid.

  • December 11, 2017

    EnCap Pours $300M Into New Texas Mineral, Royalty Co.

    Fort Worth, Texas-based mineral and royalty company Pegasus Resources LLC on Monday announced its formation alongside a $300 million equity commitment from private equity firm EnCap Investments LP.

  • December 11, 2017

    Balfour Pacific Venture Drops $78M On 2 Ill. Buildings

    A joint venture of Hamilton Partners and a Balfour Pacific Capital Inc. private equity real estate fund has purchased a pair of office buildings outside Chicago for $78.3 million, according to an announcement on Monday from sell-side broker Holliday Fenoglio Fowler LP.

  • December 11, 2017

    Private Equity Powered Energy M&A In 2017

    Energy dealmaking in 2017 saw private equity firms continue to shower the oil and gas industry with cash, while a pair of power sector megadeals highlighted the hazy future facing independent power producers. Here are five mergers and acquisitions trends that stood out to energy attorneys this year.

  • December 8, 2017

    The Law Firms Of The 2017 MVPs

    Law360's MVP award goes to attorneys who have distinguished themselves from their peers in litigation, deals and other complex matters. Find the MVPs at your firm here.

  • December 8, 2017

    Law360 MVP Awards Go To Top Attorneys From 78 Firms

    The elite slate of attorneys chosen as Law360’s 2017 MVPs have distinguished themselves from their peers by securing hard-earned successes in high-stakes litigation, complex global matters and record-breaking deals.

  • December 8, 2017

    Chancery Tosses Suit Over Earnouts In $1.4B Lone Star Deal

    A Delaware Chancery judge ruled Friday that a lawsuit from pipe and brick company HBMA Holdings LLC over earnout payments from its $1.4 billion sale to Lone Star Funds belongs in arbitration, but it was too late for the seller to press claims in court if that process fails.

  • December 8, 2017

    Vitamin World Cleared For Ch. 11 Auction With $28M Floor

    A Delaware bankruptcy judge gave Vitamin World Inc.’s auction the nod Friday after a last-minute change that brought in a new stalking horse bidder and upped the floor price to $28 million, staving off previous fears the chain would have to liquidate all of its roughly 300 locations.

  • December 8, 2017

    Biotech Denali Therapeutics Tops 3 IPOs Totaling $506M

    Shares of Denali Therapeutics Inc. soared Friday after the company raised $250 million in an upsized initial public offering that amounted to the largest biotechnology IPO of 2017, leading one of three newly public companies that raised $506 million combined.

  • December 8, 2017

    Gilead Snaps Up PE-Backed Biotech In $567M Deal

    Biopharmaceutical firm Gilead Sciences Inc. said Thursday it will acquire private equity-backed biotechnology company Cell Design Labs Inc. for $567 million in a deal that will see Gilead build up its cell therapy capabilities even more.

  • December 8, 2017

    Real Estate Rumors: LeBron James, Fla. Lots, Hubb NYC

    LeBron James has reportedly dropped $23 million on a second home in West Los Angeles, a pair of contiguous lots in Florida have reportedly sold for a combined nearly $30 million, and Hubb NYC is said to have picked up multiple retail condos in New York from a venture that includes private equity shop Carlyle Group for nearly $24 million.

  • December 8, 2017

    Real Estate Brokerage Leads 3 IPOs Set To Raise $762M

    Three companies are set to raise about $762 million combined from initial public offerings during the week of Dec. 11, led by a commercial real estate broker, private equity-backed cable equipment maker and biotechnology company, a small lineup that marks the start of a year-end slowdown.

  • December 8, 2017

    Deals Rumor Mill: Bayer, Toshiba, Alexion Pharmaceuticals

    The European Commission is wary of Bayer’s blockbuster buyout of Monsanto, Toshiba and Western Digital have come to terms on a settlement that will end their dispute over the planned 2 trillion yen sale of Toshiba Memory Corp., and Elliott Management is pushing for changes at Alexion Pharmaceuticals.

  • December 8, 2017

    Don't Miss It: Hot Deals & Firms We Followed This Week

    With so much mergers and acquisitions news in the last two weeks, you may have missed several deals announced in recent days helmed by law firms including Sidley Austin LLP and Vinson & Elkins LLP.

  • December 7, 2017

    Trusts Assert Control In $22M CFPB Student Loan Suit

    The recently affirmed owner of a $12 billion fleet of securitized student loan trusts moved late Wednesday to lock in its authority to settle a regulatory agency’s pending $22 million federal consent decree over debt collection practices, despite a seeming slowdown in the Delaware case.

  • December 7, 2017

    2 Biotech Cos., Payday Lender Tap IPO Market For $307M

    Two venture-backed biotechnology firms and a private-equity backed payday lender raised a combined $307 million from initial public offerings — pricing at the middle or bottom of their respective ranges — while another life science company upsized its planned IPO on Thursday.

Expert Analysis

  • 6 Things You Need To Know About Millennial Jurors

    Zachary Martin

    Millennials are now the largest living generation and comprise one-third of jurors. While it is impossible to generalize a group so large and diverse, trial lawyers should be mindful of certain generational differences, say baby boomer Lee Hollis and millennial Zachary Martin of Lightfoot Franklin & White LLC.

  • Series

    40 Years Of FCPA: A View From The Monitorship Trenches

    Gil Soffer

    There have been many articles on the corporate monitor selection process, but you will find little guidance on how to prepare yourself for a job that has few parallels. There are three key lessons I have learned over the course of a Foreign Corrupt Practices Act monitorship still in progress, says Gil Soffer of Katten Muchin Rosenman LLP.

  • Another Page In The Issuer-Bondholder Playbook

    Adam Summers

    When a borrower finds itself in a distressed situation, management or private equity sponsors will often identify valuable assets to isolate them from the distressed company, often to the detriment of certain creditors. A recent example involving Algeco Scotsman offers important takeaways for issuers as well as bondholders, say Adam Summers and Corey Fersel of Fried Frank Harris Shriver & Jacobson LLP.

  • The Trump Administration’s Move Against SEC Judges

    Daniel Walfish

    The government’s new position on the constitutionality of the U.S. Securities and Exchange Commission’s administrative law judges is more far-reaching and potentially consequential than is generally understood, says Daniel Walfish, a former SEC senior counsel now with Milbank Tweed Hadley & McCloy LLP.

  • Series

    40 Years Of FCPA: The Untold Story Of The Resource Guide

    Charles Duross

    Much has been written about the 2012 "Resource Guide to the U.S. Foreign Corrupt Practices Act," but no one has talked about the behind-the-scenes work that produced the guide — until now, say Charles Duross, former chief of the FCPA Unit at the U.S. Department of Justice, and Kara Novaco Brockmeyer, former chief of the FCPA Unit at the U.S. Securities and Exchange Commission.

  • An Optimistic M&A Outlook For 2018

    Jeffrey Gifford

    Many corporate executives and advisers expect the market for M&A to strengthen next year. Here, Jeffrey Gifford and Meagan McKeown of Dykema Gossett PLLC discuss why deal makers are optimistic.

  • Series

    40 Years Of FCPA: A Journey From Conviction To Dismissal

    Janet Levine

    The twist in the Lindsey Manufacturing Foreign Corrupt Practices Act case was the truncated time in which we prepared. Having refused to waive their rights to a speedy trial, our clients took control of the case — this, along with the compressed time frame, forced the government to make errors, say Janet Levine, Sima Namiri-Kalantari and Megan Weisgerber of Crowell & Moring LLP.

  • Series

    40 Years Of FCPA: The Siemens Lesson — Tillerson Is Right

    solmssen.jpg

    Since its whopping $800 million Foreign Corrupt Practices Act settlement in 2008, Siemens cleaned up — and it has “cleaned up” in its long-standing competition with General Electric. How? As Secretary of State Rex Tillerson reportedly told President Donald Trump, you don’t need to pay bribes to succeed in international business, says Peter Y. Solmssen, former general counsel of Siemens.

  • Series

    40 Years Of FCPA: The Rise In International Enforcement

    Scarboro.jpg

    The 2008 Siemens matter — then the largest sanction ever imposed in a Foreign Corrupt Practices Act enforcement action — set the stage for future cross-collaboration in global anti-corruption enforcement, say Cheryl Scarboro, former chief of the FCPA Unit at the U.S. Securities and Exchange Commission, and Diana Wielocha of Simpson Thacher & Bartlett LLP.

  • Bringing Cayman Derivative Claims In NY Just Got Easier

    Robert Quirk

    The New York high court’s recent holding in Davis v. Scottish Re Group removes a significant practical hurdle to bringing derivative claims involving Cayman Islands corporations. With the Cayman leave-of-court rule out of the picture, shareholders need not arrive at the courthouse door already equipped with evidence to support their claim, say Rob Quirk and Stephen Younger of Patterson Belknap Webb & Tyler LLP.